US 12,268,690 B2
Treatments for mutations in acute myeloid leukemia
Jeffrey W Tyner, Portland, OR (US); Cristina Tognon, Portland, OR (US); Brian J Druker, Portland, OR (US); Daniel Bottomly, Beaverton, OR (US); Beth Wilmot, Portland, OR (US); Stephen Kurtz, Portland, OR (US); Samantha Savage Stevens, Portland, OR (US); Nicola Long, Portland, OR (US); Anna Reister Schultz, Beaverton, OR (US); Elie Traer, Portland, OR (US); and Shannon K McWeeney, Portland, OR (US)
Assigned to Oregon Health & Science University, Portland, OR (US)
Appl. No. 17/263,531
Filed by OREGON HEALTH & SCIENCE UNIVERSITY, Portland, OR (US)
PCT Filed Jul. 26, 2019, PCT No. PCT/US2019/043759
§ 371(c)(1), (2) Date Jan. 26, 2021,
PCT Pub. No. WO2020/023921, PCT Pub. Date Jan. 30, 2020.
Claims priority of provisional application 62/711,452, filed on Jul. 27, 2018.
Prior Publication US 2021/0235374 A1, Jul. 29, 2021
Prior Publication US 2024/0033265 A2, Feb. 1, 2024
Int. Cl. A61K 31/519 (2006.01); C12Q 1/6886 (2018.01)
CPC A61K 31/519 (2013.01) [C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 5 Claims
 
1. A method of treating Acute Myeloid Leukemia in a human, wherein the Acute Myeloid Leukemia is characterized by a mutation at least in the NPM1 gene, the method comprising administering to the human in need thereof a therapeutically effective amount of ibrutinib, or a pharmaceutically acceptable salt thereof.